4D Molecular Therapeutics, Inc. (FDMT) Stock Overview
Explore 4D Molecular Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
4D Molecular Therapeutics, Inc. (FDMT)
Key Financials
Key Financials
Market Cap
795.6M
P/E Ratio
-5.54
EPS (TTM)
$-2.57
ROE
-0.41%
FDMT Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, 4D Molecular Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of FDMT on the NASDAQ shows an RSI of 61.07, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $8.21 for the NASDAQ listing.
Key metrics behind 4D Molecular Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -5.54 and a market capitalization of 795.6M. Combined with our AI analysis, these give both institutional and retail investors a clear view of FDMT on the NASDAQ.